According to researchers, the adapted treatment could help to prevent muscle damage and permanent physical impacts.

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

A new study shows mRNA-based treatment can protect muscle tissue from snake venom damage, offering a potential boost to ...

The success of mRNA technology and its potential uses in therapeutics and preventative medical treatment may create a new technology ecosystem, the Harvard Business Review reported April 18. As has ...

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the blueprint for functional proteins in the body and induces therapeutic effects.

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

Developers of mRNA therapeutics face an increasingly complex landscape: rising expectations for potency and durability, ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test out a vaccine against norovirus, a frequent and ...

Mycobacterium tuberculosis (Public Health Image Library, NIAID, Image ID: 18139) Mycobacterium tuberculosis (Public Health Image Library, NIAID, Image ID: 18139) Tuberculosis (TB) is the number one ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. JR Whalen: Here's your mid-day brief for Friday, July 23rd. I'm J.R. Whalen for ...